Bedrijfsoverzicht
Nkarta, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to the development and commercialization of natural killer cell therapies designed to treat cancer and autoimmune diseases. This business operates within the Healthcare sector, specifically targeting the Biotechnology industry, where the focus is on utilizing biological agents for therapeutic intervention rather than small-molecule drugs. The company currently maintains a market capitalization of $154.70M and employs a workforce of 108 individuals. Its annual revenue is not disclosed in the available financial data, indicating that the firm is likely in a pre-revenue or early-stage revenue generation phase typical of clinical-stage entities. The market cap figure of $154.70M reflects a significant valuation for a company with no reported sales, suggesting that the market price is primarily driven by the potential of its lead product candidate, NKX019, rather than current cash flow generation. This valuation implies that the company's position is heavily reliant on the successful progression of its clinical trials and regulatory approvals rather than established commercial sales.
Financiële gezondheid
The company reports a net income of -$104,084,000 and an EBITDA of -$106,645,000, while the reported revenue is not available in the dataset. The substantial gap between the negligible or unreported revenue and the deep net losses reveals an aggressive cost structure characterized by high research and development expenditures typical of clinical-stage biotechnology firms. Free cash flow stands at -$53,593,752, which indicates a negative financial flexibility where cash burn outpaces operating cash generation, necessitating external capital raises to fund ongoing operations. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that indicates the company has not yet achieved profitability or has reported revenues that do not cover direct costs in a way that generates positive margins. On the balance sheet, the company holds $276.28M in cash against $76.42M in debt, creating a robust liquidity buffer despite the negative earnings. The debt-to-equity ratio is 24.47, which, when viewed alongside the substantial cash reserves, suggests a leveraged capital structure that is manageable given the available cash on hand. The current ratio is reported at 12.69, a metric that indicates exceptionally strong short-term liquidity and the ability to cover current liabilities with current assets many times over. Return on Equity is -28.9% and Return on Assets is -16.0%, figures that reveal that management effectiveness is currently measured by capital preservation and advancement of clinical assets rather than the generation of shareholder returns.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not available due to the lack of positive earnings, while the forward P/E is listed as -1.21. The negative forward P/E implies that the market is pricing in future earnings that are not yet realized, a common scenario for pre-profitable biotechnology companies where valuation is disconnected from current earnings performance. The price-to-book ratio is 0.49, indicating that the stock trades at less than half of its book value, which suggests the market does not currently assign a significant premium to the company's intangible assets or future pipeline potential. The price-to-sales ratio is not available, and the EV/EBITDA stands at 0.42, a valuation metric that is exceptionally low for a clinical-stage company and suggests the market is applying a conservative multiple to the entity's enterprise value. The stock has reached a 52-week high of $2.81 and a 52-week low of $1.60, placing the current trading price within this historical range but reflecting significant volatility typical of the sector. The beta value of 0.67 indicates that the stock is less volatile than the broader market, moving with 33% less intensity than the overall market index. This lower beta suggests that while the company is subject to biotechnology-specific risks, its price movements are somewhat dampened relative to the general market fluctuations.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both not available, as the company has not yet generated consistent positive earnings or sales data to calculate growth rates. Without positive revenue figures, it is impossible to determine if earnings are growing faster or slower than revenue, as the fundamental growth trajectory is currently defined by clinical milestones rather than financial expansion. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning no dividends are distributed to shareholders. This approach implies that the company reinvests all available capital, including its substantial cash reserves, directly into research and development activities to accelerate the clinical progress of NKX019. The overall growth and income profile is characterized by a complete reliance on capital markets for funding, with no current income generation from operations. The absence of dividends and the negative financial metrics confirm that the business model is purely capital-intensive and focused on long-term asset creation rather than short-term shareholder yield.